| Ytd | 31.15% | |
| 1y | -20.34% |
| Open | 17.89 | Prev Close | 18.03 | Low | 17.66 | High | 18.15 | Mkt Cap | 1.11B |
| Vol | 148.18K | Avg Vol | 974.22K | EPS | -1.64 | P/E | N/A | Forward P/E | -6.87 |
| Beta | 2.50 | Short Ratio | 9.28 | Inst. Own | 101.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 16.09 | 200-d Avg | 15.81 | 1yr Est | 36.24 |
JANX News
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list.
Wolfe Research analyst Kalpit Patel upgrades Janux Therapeutics (NASDAQ:JANX) from Peer Perform t
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh in
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks C
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.35) per share which beat the analy
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha
Truist Securities analyst Supawat Thongthip assumes Janux Therapeutics (NASDAQ:JANX) with a Buy r
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the s
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates,
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.39 per share versus the Zacks C
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While
Janux Therapeutics, Inc. is upgraded to Strong Buy, trading below cash value with a robust cash runw
Jones Trading analyst Boris Peaker maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowe
Janux Therapeutics halts JANX008 after Phase 1a review, shifting focus to higher-priority programs d
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biop
Barclays analyst Etzer Darout downgrades Janux Therapeutics (NASDAQ:JANX) from Overweight to Unde
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha
UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers
JANX earns $35M milestone payment from Bristol Myers as TRACTr-based cancer candidate advances, sign
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha
Shares of Janux Therapeutics, Inc. (NASDAQ: JANX - Get Free Report) have been assigned an average ra
Cantor Fitzgerald analyst Josh Schimmer maintains Janux Therapeutics (NASDAQ:JANX) with a Overwei
Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers t
Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.51) per share which beat the analy
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopha
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JAN
Wall Street analysts are placing aggressive bets on four clinical-stage biotech companies, with cons
The average of price targets set by Wall Street analysts indicates a potential upside of 319.2% in J
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company dev
Janux Therapeutics signs a global licensing deal with Bristol Myers Squibb worth up to $800 million.
Janux Therapeutics, Inc. (NASDAQ:JANX) ("Janux"), a clinical-stage biopharmaceutical company
Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold
Piper Sandler analyst Kelsey Goodwin maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developin
Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Overweight and lo
Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers th
JANX stock hit 52-week low after releasing Phase 1 data for JANX007 in mCRPC. Encouraging efficacy a
